[ad_1]
UAE-based leading artificial intelligence company G42 and Abu Dhabi sovereign investor Mubadala will combine their respective healthcare businesses to create a new, first-of-its-kind integrated healthcare company.
By combining G42 Healthcare’s unique medical and data-centric technologies with Mubadala Health’s world-class patient care, the new entity will seek to revolutionize the regional healthcare landscape and provide a new approach to patient-centric personalized care .
The two organizations already serve hundreds of thousands of patients each year. The new entity will leverage the strengths of this combined network, including state-of-the-art medical facilities and digital platforms, to enhance patient services throughout the care process.
Frontiers in Medical Research
The new company will be at the forefront of medical research and innovation and will be a vertically integrated healthcare giant delivering groundbreaking clinical solutions to help solve the world’s most critical health and diagnostic challenges. Hasan Jasem Al Nowais has been appointed CEO of the new entity and will continue to lead Mubadala Health.
Xiao Peng, CEO of G42 Group, said: “Our goal is to unlock medical super-intelligence based on the respective strengths of G42 Medical and Mubadala Medical to help global medical expansion. Our capabilities and experience in leveraging data and artificial intelligence will bring Allowing us to continue transforming the traditional healthcare ecosystem, delivering best-in-class patient care in world-class facilities, fueled by the latest breakthrough research.”
Waleed Al Mokarrab Al Muhairi, Chairman of Mubadala Health and Deputy Chief Executive Officer of Mubadala, said: “The future of healthcare lies in the incredibly rapid development of technology. For over a decade, Mubadala has served UAE residents in a number of specialties Delivering the highest standard of patient care. We now seek to take patient care to the next level, entering a new era of precision and personalized medicine.”
Optimize clinical outcomes
Al Nowais said: “The new company represents a truly integrated healthcare ecosystem where research, technology, artificial intelligence and genomics combine with world-class care to optimize clinical outcomes. We are committed to ensuring our exceptional physicians and Teams of paramedics have access to groundbreaking medical technologies and provide patients with unparalleled care.”
While continuing to build its network in the UAE, the new company will consider opportunities for international expansion and new partnerships. The new entity will also focus on collaboration with leading researchers and the pharma and health technology ecosystem, leveraging the UAE’s progressive and future-focused regulatory framework to bring world-class care to local communities.
In both organisations, today’s healthcare assets include: Imperial College London Diabetes Centre; Health Point; National Reference Laboratory; Health Plus; Danat Emarat; Moorfields Eye Hospital, Abu Dhabi; Biogen Power; the UAE Centre of Excellence for Omics; and Insights Research Organization & Solutions (IROS), the first contract research organization in the UAE to specialize in healthcare research. arab trade news agency
[ad_2]
Source link